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Abstract
Uveitis is reported to be related to tuberculosis in 0.2–20% of cases. This large 
range reflects prevalence variations of tuberculosis around the globe as well as dif-
ferences in diagnostic criteria. In addition, patients with noninfectious uveitis are 
frequently treated by immunomodulatory drugs and are thus at risk of TB reactiva-
tion. Search for tuberculosis infection is thus an important aspect in the work-up of 
patients with uveitis, even in low prevalence area. In the work up of such patients, 
the first question to ask is whether the patient has been infected by mycobacterium 
tuberculosis or not. The second question is to determine whether the uveitis is due 
or linked to this mycobacterial infection or not. Classical tuberculosis screening 
tools are used to answer the first question (TST, IGRA and chest X ray). The answer 
to the second question is much more challenging and will require the exclusion of 
other causes, to consider epidemiological data and clinical signs, polymerase chain 
reaction (PCR) on ocular fluids and therapeutically treatment trial. Disease preva-
lence will greatly influence all proposed tests and the final diagnosis. Tuberculosis 
prevalence in Western countries has progressively decreased during the twentieth 
century but remains elevated in cities with large migrating populations and drug 
addicts, with an increase of ultra-resistant cases. All those data must be carefully 
analyzed in order to collect enough evidences supporting tuberculosis uveitis before 
the initiation of a treatment with potential serious side and adapt the treatment to 
the increasing resistance.
Keywords: tuberculosis, uveitis, immunosuppressive agents, immunomodulatory 
agents
1. Introduction
Tuberculosis (TB) is a worldwide problem and a main concern for the World 
Health Organization. Nowadays, 30% of the human population is infected with 
the Koch bacillus and tuberculosis remains one of the major health problems on 
earth [1–4]. In 2014 alone, 9.6 million people were thought to be infected with 
Mycobacterium tuberculosis (Mtb) globally, in the vast majority of cases, infec-
tion leads to a latent form of tuberculosis, active disease being found in only 10% 
[1]. Latent tuberculosis (LTBI) occurs when individuals have been exposed to TB 
but remained systemically healthy. This latency relies on the presence of an active 
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immune response against Mtb. All those people are thus at risk of TB reactivation 
in case of immunodepression. With area of globalization, all countries are affected 
with varying rates of infection, with high endemic countries from where migrant 
groups settle.
Uveitis is reported to be related to tuberculosis in 0.2–20% of cases [5]. This 
large range reflects prevalence variations of tuberculosis around the globe as well as 
differences in diagnostic criteria. The etiological relationship between tuberculosis 
and ocular inflammation is complex. Hence, direct demonstration of the presence 
of Mtb inside the eye is fairly rare because of the pauci-bacillary nature of the infec-
tion. If the patient has the evidence of systemic active TB infection, the uveitis may 
indicate direct ocular involvement by Mtb. However, in most cases, a diagnosis of 
presumed ocular tuberculosis will be made on the basis of the presence of compat-
ible ophthalmological signs in the setting of a systemic (usually latent) infection 
[6–8]. In this context, recent studies suggest that in patients with vision-threatening 
uveitis with no identifiable cause who have LTBI, the recurrence rate of uveitis is 
greatly reduced with concomitant anti-tubercular therapy (ATT) and immunosup-
pressive treatment [9–11]. Another important issue, reopened with the introduction 
of biologics, is obviously the risk of inducing tuberculosis reactivation in patients 
with severe vision- threatening non-infectious uveitis where systemic corticoste-
roids and steroid-sparing agents are required. Search for tuberculosis infection 
is thus an important aspect in the work-up of patients with uveitis, even in low 
prevalence area in order to prevent reactivation of LTBI [10]. In this chapter, we will 
review those important aspects of the relation between TB and immunosuppressive 
(IS) drugs/immunomodulatory treatment (IMT) in uveitis patients.
2.  Screening in non-infectious uveitis patients for LTBI infection before 
starting IS or IMT
The mainstay therapy of sight-threatening noninfectious uveitis is based on 
corticosteroids and immunosuppressive drugs administration. IS drugs are usually 
restricted to refractory cases and to patients requiring high doses of steroids, in 
which visual prognosis depends on more aggressive therapeutic approaches. Their 
long-term use is limited by ocular and systemic side effects.
The introduction of biological agents such as anti- tumor necrosis factor (anti 
TNF-α), which is a key cytokine in host defense against intracellular infection as 
Mtb, by regulating the integrity of granuloma where TB is contained, led to the 
upsurge of TB reactivation [12]. In contrast, none anti-TNF-α targeted biologics 
like IL-6 inhibitor tocilizumab (TCZ), anti-CD20 rituximab (RTX) and more are 
not likely associated to any increase risk [13]. To date available TNF alpha booking 
agents are: infliximab (IFX), adalidumab (ADA), golimumab (GOL), certolizumab 
peg (CZP) which are monoclonal antibodies directed against TNF alpha, and 
etanercept (ETN) which is a soluble receptor blocking agent. Several publications 
reported the effectiveness of anti TNF- drugs in the treatment of uveitis [14, 15]. 
Anti-TNF treatment had a profound effect on the management of autoimmune 
vision threatening uveitis with known etiology. ADA is the first licensed anti-TNF 
treatment for uveitis patients. It is important to emphasize that anti-TNFα agents 
(infliximab, adalimumab, golimumab) may be more efficient than soluble receptors 
of TNFα (etanercept) in decreasing the risk of uveitis [16]. But also paradoxi-
cal reactions during treatment with a biologic agent, like palmoplantar pustular 
and psoriasiform reactions, psoriatic arthritis, hidradenitis, inflammatory bowel 
disease, pyoderma gangrenosum, granulomatous reactions, and vasculitis have 
subsequently been reported through anecdotal cases, cohort studies, and analysis of 
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drug event databases, showing also that uveitis can flare during anti-TNF-α therapy 
especially with etanercept [17].
Because of the risk of developing active systemic TB, screening strategies 
for LTBI detection and preventive therapy for patients undergoing therapy with 
biological agents have been developed. LTBI is detected either by tuberculin skin 
test (TST), also named Mantoux test, or by blood-based interferon-gamma release 
assay (IGRA) including QuantiFERON TB Gold in Tube (QFT). Based on the WHO 
recommendations, either TST or IGRA are acceptable for LTBI screening [18]. 
Clinicians may consider, before starting IS, to use IGRA in persons with a history of 
BCG, but if the index of suspicion of LTBI is high, independently of BCG vaccina-
tion, both IGRA and TST may be done, especially prior to initiating anti TNF-α 
therapy [19]. Recent studies have evaluated the effectiveness of QFT and TST in 
the screening of arthritis patients and patients with inflammatory bowel disease 
[20, 21]. Concordance between the two tests was moderate, and it appears lower 
with immunosuppression. QFT alone may be appropriate in immunosuppressant-
naïve patients but both tests should be considered in immunosuppressed patients. 
In guidelines pertaining to medical immunosuppression, the recommendations 
for screening varied considerably between the use of TST and IGRA. Concurrent 
testing with both TST and IGRA was supported by many guidelines [19–23]. Lu 
et al. conducted a systematic review and meta-analysis to compare the accuracy of 
IGRAs and TST for the diagnosis of Mtb [24]. IGRAs showed better performance 
than TST for the diagnosis of the tuberculosis. Data on comparative and cumulative 
sensitivity and specificity indexes for both tests are detailed in Table 1. Cotter and 
Rosa et al. reported an interesting approach to choose the eligibility for treatment 
of LTBI after screening with TST and IGRA in immunosuppressed and immuno-
competent patients suffering from inflammatory bowel disease, based on a very 
practical algorithm adapted from Duarte et al. to trace the routes to be followed to 
decide which patients has LTBI and need tuberculosis treatment according to IGRA 
and TST [25]. We think that this algorithm can be extrapolated to all patients with 
inflammatory diseases like uveitis (Table 2). Patients with inflammatory diseases 
who require long-term maintenance medical immunosuppression with a negative 
screening TST or IGRA may not need further evaluation in the absence of risk 
factors and/or absence of clinical suspicion for TB in low TB risk countries [19, 21]. 
Annual evaluation is highly recommended if they live, travel, or work in situations 
where TB exposure is likely while they continue treatment with biologic agents [23]. 
It is important to decrease false-positive LTBI testing that may lead to potential 
toxic antibiotic treatment and result in the unnecessary interruption of biologic 
therapy. After screening, if either test is positive (TST or IGRA), a chest CT- Scan is 
mandatory to exclude active pulmonary TB.
LTBI can progress to active TB in 5–10% in subjects who are at higher risk like 
recent contact, people leaving with HIV, children below 5 years, also an age > 65, 
immigrants from high TB prevalence countries and candidates of biological 
Table 1. 
Data on comparative and cumulative sensitivity and specificity indexes of IGRAs and TST for the diagnosis of 
tuberculosis.
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treatment [18]. When the patient is evaluated, clinicians should also take in account 
other variables including the host-related TB risk based on age, socioeconomic 
status, lifestyle, malnutrition, immune-suppression conditions and co-morbidities. 
The underlying disease itself is also associated with a higher TB risk, with a peak 
ranging from 2.0 to 8.9 in rheumatoid arthritis patients not receiving biologic 
therapies, and a lower risk in those with ankylosing spondylitis (AS), psoriatic 
arthritis (PsA), and psoriasis (Pso) [21–23, 26]. Systemic TB reactivation has rarely 
been reported as side effect related to Anti-TNF-α therapy in patients with refrac-
tory relapsing chronic posterior uveitis [14, 15]. A review of the US Food and Drug 
Administration (FDA) Adverse Event Reporting System data revealed 70 cases of 
active TB in 147,000 patients receiving IFX worldwide [22]. Of these, 47 occurred 
in patients with RA, 18 in those with Crohn’s disease, and 5 in people with other 
types of arthritis, with a median interval of 12 weeks from starting the biologic 
therapy. The incidence rate of TB was 4 times higher in IFX-treated patients with 
RA than the estimated incidence in people with RA not receiving biologic therapy. 
As mentioned, there is an evidence of single biological-related risk as reported 
by Cantini et al. [10]. The risk is at least 3–4 times higher in patients exposed to 
monoclonal antibodies IFX and ADA than in those receiving the soluble receptor 
ETN. Subsequent studies aimed to establish the relative risk (RR) of TB in patients 
using TNF-α inhibitors (and other biologics) compared to that in the general 
population. Registries for patients on biologics have provided a valuable resource 
for studies that aimed to determine the risk of TB associated with these therapies. A 
French study using the RATIO registry found age- and sex-standardized incidence 
ratios (SIR) for infliximab, adalimumab, and etanercept of 18.6 (95% CI, 13.4–25.8), 
29.3 (95% CI, 20.3–42.4), and 1.8 (95% CI, 0.7–4.3), respectively, compared to that 
in the general population [27].
Of note, the combined use of anti-TNF agents and traditional DMARDs exposes 
to a higher risk of TB reactivation in subjects with LTBI compared to patients 
treated with anti-TNF-α monotherapy. But practicians need to be aware that 
patients with inflammatory diseases, for which biologics are prescribed, already 
have an increased risk of TB associated with their immunosuppressed disease state 
and often also have co-morbidities and additional medications that themselves have 
an increased risk of TB compared to that of the general population [28]. The risk 
Table 2. 
Algorithm for treatment of latent tuberculosis infection in uveitis patients adapted from Duarte et al.
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of TB reactivation in inflammatory patients treated with non-anti-TNF-α target 
biologics like IL-6 inhibitor tocilizumab (TCZ), anti-CD20 rituximab (RTX) and 
IL-1 inhibitor anakinra (ANK) and more are not likely associated to any increase 
risk [13, 29, 30].
Recommendations state that in the case of a diagnosis of LTBI (positive score 
to an immune diagnostic test (TST or IGRA) and a chest radiograph negative for 
active TB lesions), active TB prevention with a 6–9-month course of isoniazid is 
recommended associated to pyridoxine supplementation (vitamin B6), with an 
average protective effect against TB of 60% during the observation period [31]. 
There is no clear evidence in the literature concerning the optimal interval between 
the beginning of the preventive therapy for TB reactivation and biologic therapy 
[23]. Biologic therapy is suggested to be postponed for at least 1 month thereafter. 
Therefore, the decision to treat an individual must balance the potential personal 
benefits against the risk of drug hepatotoxicity and neurotoxicity which is higher in 
chronic alcoholics, malnourished persons, and pregnant women or healthy indi-
viduals (0.2%) due to the inhibitory effect of isoniazid on the function of pyridox-
ine metabolites. Daily rifampicin alone for 3–4 months compared to placebo has 
shown a 59% reduction of incident TB [32]. A multi-center clinical trial comparing 
4 months of self-administered rifampicin to 9 months of daily isoniazid therapy 
has been recently completed in 2017. Daily therapy with isoniazid plus rifampicin 
for 3 months and standard therapy with isoniazid for 6–12 months were equivalent 
in terms of efficacy and as expected, given the shorter regimen and direct observa-
tion, treatment completion was significantly higher in the combination therapy 
group (82.1% vs. 69.0%). Toxicity was also less reported in the shorter regimen, 
with fewer individuals taking rifampicin/isoniazid developing drug-related hepato-
toxicity [33].
Considering the most frequently used IS and IMT drugs for treatment of 
non-infectious uveitis, a few specific ophthalmologic reports aims to provide an 
overview on their use in patients with a recent or past history of systemic serious 
infection presumably unrelated to their inflammatory eye diseases (IED) [34]. 
Recently, an expert committee considered assessment and investigation of patients 
with severe IED initiating immunosuppressive and/or biologic therapy [35]. 
Infections that may be exacerbated or reactivated as a result of systemic immuno-
suppressive of biological therapy include: Tuberculosis, hepatitis B virus, hepatitis 
C virus, HIV and toxoplasmosis. These infection risks should be assessed or exclude 
before the initiation of such therapy. We keep our focus on risk of TB reactivation in 
IED patients. Studies regarding this issue are mainly focused on biological therapy, 
although some studies have indicate the potential risk for developing a TB when 
using traditional IS agents, particularly MTX [36]. But a significant relationship 
between the use of MTX and increased incidence of active TB was not established 
but should be still considered.
While it has been described that If TB develops during anti-TNF-α treatment, 
it is more likely to be disseminated and extra- pulmonary than are other TB cases. 
Few reports addressed the occurrence of uveitis tuberculosis development during 
anti-TNF treatment. A French group reported the uveitis cases occurring in patients 
with chronic rheumatic diseases, chronic inflammatory intestinal diseases or con-
nective tissue diseases, while treated with disease-modifying anti-rheumatic drugs 
(DMARDs) and/or biologic therapies. A total of 32 cases of uveitis were reported, 
and 5 were of infectious origin, 2 toxoplasmosis, 2 herpes virus and 1 tuberculosis 
[37]. We faced one case of patient with SA and anterior uveitis treated with ADA for 
years, who developed a panuveitis with choroidal granulomas (Figure 1), associ-
ated with progressive cough, dyspnea, and pyrexia. A computed tomographic scan 
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revealed extensive thoracic lymphadenopathy and interstitial shadowing of the 
lungs. Culture and polymerase chain reaction (PCR) of a mediastinal lymph node 
biopsy specimen showed acid-fast bacilli.
3. Ocular tuberculosis and IMT
There is a great deal of ambiguity in establishing a firm relationship between 
tuberculosis and ocular inflammation. It’s not uncommon, when investigating 
patients with uveitis, that there is no identifiable systemic or ocular disease and 
that the only positive test is Mantoux test or QFT associated or not to abnormalities 
on the chest X-ray. In those patients classically classified as idiopathic uveitis, and 
treated by immunomodulation, the role of Mtb in disease development has been 
questioned. On the other hand, the role of immunomodulation in the treatment of 
well-established tubercular uveitis is also debated.
Severe studies tried to establish a cause/effect relationship between TB and 
uveitis using some criteria for presumption of tubercular etiology including posi-
tive Mantoux test/QFR, healed lesions on the chest X-ray, no other etiology, and 
suggestive clinical presentation of uveitis [5, 6]. In such patients, the question arises 
as to whether the uveitis is related to TB or not, leading to the other question of 
establishing or not ATT.
Intra-ocular TB accounts for 6.9–10.5% of uveitis cases without a known active 
systemic disease and 1.4–6.8% of patients with active pulmonary disease have con-
current ocular TB [38, 39]. In some patients there is a direct invasion by TB myco-
bacterium, into local ocular tissues, such as in choroidal granuloma, as evidenced 
by the histopathological examination of the biopsied involved ocular tissue, smears 
and cultures of the tissue fluid, and the polymerase chain reaction (PCR). In other 
patients, there is no clinical evidence to suggest active ocular TB infection. The 
pathogenesis of uveitis in these patients remains unclear. It is uncertain whether 
the uveitis is the result of reactivation of LTBI or a hypersensitivity response to Mtb 
[38, 40]. Bansal proposed guidelines for the diagnosis of intra-ocular TB includ-
ing a combination of clinical ocular findings, ocular and systemic investigations, 
exclusion of other etiology and response to ATT [41]. Based on these and their own 
results, Gupta et al. proposed to classify intra-ocular TB into confirmed, probable, 
and possible intra-ocular TB [11]. Recently The Collaborative Ocular Tuberculosis 
Study (COTS)-1 tried to clarify through a multinational retrospective review, 
Figure 1. 
Bilateral tuberculosis panuveitis developing in a SA patients while under ADA therapy. (A) Eye fundus 
of the right eye displayed mild vitritis with yellowish deep round infiltrate lesion with discrete subretinal 
hemorrhage; (B) fluorescein angiogram (FA) at early phase revealed some multifocal hypofluorescent 
areas, which were easily seen on early stage indocyanin green angiogram (ICG); (C) ICG revealed larger 
hypofluorescent areas, better delimitated with sharp edges, confirming the choroidal localization of these 
multiple lesions corresponding to tuberculous granulomas.
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what are the suggestive clinical features and approach to diagnosis of patients with 
tubercular uveitis. The diagnostic criteria for tubercular uveitis used in COTS-1 are 
developed in Table 3 [42]. Based on those criteria, we propose a diagram explaining 
the diagnostic pathways for patients suspected of having TB (Table 4). In 2018, 
they provided in more details the different phenotypes of choroidal involvement 
in tubercular uveitis, also geographical variations in the phenotypic expression 
and treatment outcomes. The phenotypic variants reported were serpiginous-like 
choroiditis (SLC) in 46.1%, choroidal tuberculomas (CTC) in 13.5%, and multifo-
cal choroiditis (MFC) in 9.4%. Other rare phenotypic variants of choroiditis were 
observed including ampiginous choroiditis (APC) in 9.0% and acute posterior 
multifocal placoid pigment epitheliopathy (APMPPE) in 3.3% and other indeter-
minate type of choroiditis in 18.8%. Those varied clinical phenotypes are probably 
based on the interaction and activity of mycobacterium bacilli and immune system. 
While SLC was clearly the most prevalent phenotype in the Asia Pacific region, it 
was less prevalent in the West. Furthermore, APC is a phenotype of choroiditis that 
is infrequently reported in association with tubercular uveitis [43].
Because TB can be sometimes confined purely to the eye, and as a pauci-bacillary 
infection, there is a lack of agreed management guidelines among ophthalmolo-
gists in establishing the diagnosis of intra-ocular TB. Similarly, there is no agreed 
consensus between ophthalmologists and other physicians with regards to role of 
ATT and duration of treatment in cases of isolated intra-ocular TB. Bansal et al. 
assessed the long-term impact of adding anti-tubercular treatment to the standard 
anti-inflammatory therapy consisting mostly of corticosteroids in patients with 
uveitis and evidence of latent or manifest TB. The group speculated that if uveitis 
was related to hypersensitivity reaction to tubercular antigens attributable to latent 
TB, the elimination of LTBI would lead to elimination of future recurrences of uve-
itis in these patients. The administration of anti-tubercular therapy in these patients 
Table 3. 
(COTS)-1 clarify, through a multinational retrospective review, the suggestive clinical features and approach to 
diagnosis of patients with tubercular (TB) uveitis.
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substantially reduces recurrences when given along with standard corticosteroid 
therapy. Corticosteroids may limit damage to ocular tissues caused from delayed 
type hypersensitivity [41]. The use of ATT to manage presumed ocular tuberculosis 
is regarded as an effective tool for tubercular uveitis and response to therapy can be 
a good surrogate for diagnosis of presumed ocular tuberculosis.
A case control study conducted by Chee et al. on patients with uveitis with 
evidence of latent TB and no other underlying disease, who were treated with ATT 
for more than 9 months duration, were approximately 11 times less likely to develop 
recurrence of inflammation compared with patients who had not received ATT. This 
association was independent of potential confounders such as demographics, 
classification of uveitis and corticosteroid therapy. On the other hand, patients who 
were treated with ATT for <6 months or 6–9 months duration did have a reduction 
in recurrence, but this was not statistically significant [39]. The Collaborative Ocular 
Tuberculosis Study (COTS)-1 group also reported the role of ATT in the manage-
ment of patients with TB uveitis from a multinational cohort and explore potential 
correlations of clinical features with treatment response. A low treatment failure 
rate was reported in patients with TB uveitis treated with ATT. On multivariate 
regression analysis, they showed that the presence of choroidal involvement with 
vitreous haze and snowballs in patients with panuveitis was associated with a higher 
risk of recurrence. Concerning the addition of corticosteroids to ATT, their results 
suggests that patients treated with corticosteroids may have had poorer outcomes 
than those who were not [42]. Effectively, the possible beneficial effect of immu-
nomodulation in association of ATT in the management of tubercular uveitis is still 
debated. A recent meta analyze was conducted on 37 articles to assess the effect of 
ATT associated or not to IMT on ocular outcome of patients with presumed ocular 
TB. The meta-analysis revealed that 84% of the patients receiving ATT showed 
Table 4. 
Diagram explaining the diagnostic pathways for patients suspected of having TB.
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non-recurrence of inflammation during the follow-up period. A successful out-
come was observed in 85% of patients treated with ATT alone; in 82% of patients 
treated with ATT and systemic steroids and in 85% of patients treated with ATT and 
systemic steroids and immunomodulators. It was not possible to conclude which 
regimen was the best to control ocular inflammation [44–46].
4. Conclusion
The link between tuberculosis, uveitis and immunosuppression are important 
and complex. First, patients with inflammatory diseases treated with IMT agents, 
including noninfectious uveitis patients, are at risk to develop active tuberculosis, 
including ocular tuberculosis. Secondly, many data suggest that Mtb might play a 
role in disease development of idiopathic uveitis in LTBI patients and that ATT must 
be considered in such cases. Finally, inflammatory and immune reaction are likely to 
play a role during ocular tuberculosis and immunomodulation has a beneficial effect.
In summary, we have to keep in mind that the main concern of TB screening for 
ophthalmologist is to avoid systemic TB reactivation in front of a sight threatening 
uveitis with known etiology destined to IS/IMT. But when facing an idiopathic 
uveitis under IS/IMT, there is another risks which has to be considered, the risk 
of ocular TB misdiagnosis with a non- or partial response to immunosuppressive 
treatment. Introduction of ATT in those cases will control inflammation, will help 
to discontinue most IMT and will prevent recurrences.
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